BrainStorm is currently completing a 200-patient, double-blind, placebo-controlled, repeat-dosing NurOwn Phase 3 study in the U.S. As part of its commitment, Catalent will undertake the transfer of the manufacturing process to, and provide future CGMP clinical supply of NurOwn from, its new, 32,000 square-foot cell therapy manufacturing facility in Houston, Texas. “We know that ALS patients are in urgent need of a new treatment option. On completion of the clinical trials and in anticipation of potential approval of NurOwn, the companies will look to extend the partnership to include commercial supply from the Houston facility. The FDA gave clearance to Brainstorm to launch a Phase 2 clinical trial (NCT03799718) investigating MSC-NTFs as a treatment for MS; its first patient was enrolled in March 2019. When it acquired MaSTherCell, Catalent added expertise in autologous and allogeneic cell therapy development and manufacturing to position it as a premier technology, development and manufacturing partner for innovators across the entire field of advanced biotherapeutics. It … NEW YORK, Dec. 18, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for … Isaac Mitchell - December 9, 2020. The average equity rating for BCLI stock is currently 2.00, trading closer to a bullish pattern in the stock market. BrainStorm Cell Therapeutics, Inc. (NASDAQ: BCLI) is a clinical-stage, publicly-traded biotechnology company focused on the development of best-in-class autologous cellular therapeutics for the treatment of highly debilitating neurodegenerative diseases. Catalent has a global cell and gene therapy network of dedicated, large-scale clinical and commercial manufacturing facilities, and fill-finish and packaging capabilities located in both the U.S. and Europe. However, that wasn’t the … Brainstorm Cell Therapeutics insiders own about US$12m worth of shares. © 2020 GlobeNewswire, Inc. All Rights Reserved. Brainstorm Cell Therapeutics, Inc. operates as a biotechnology company, which develops and commercializes adult stem cell therapeutic products. © Copyright 2019, BrainStorm Cell Limited. We look forward to partnering with BrainStorm and providing our stem cell manufacturing expertise as we work to optimize production and streamline the product’s path towards commercial launch.”. The Company holds the … Technologies; Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI): The most interesting shares today. It … With the company’s most recent per share price at $5.16 changing … BrainStorm has completed a phase 3 pivotal trial using repeat-administration of autologous MSC-NTF cells in ALS in the United States. Twitter. BrainStorm’s autologous MSC-NTF cell therapy is investigational and not FDA approved. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements. Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) trade information Instantly BCLI is in green as seen in intraday trades today with action 10.83%, the performance over the past five days has been red. The potential risks and uncertainties include, without limitation, BrainStorm's need to raise additional capital, BrainStorm's ability to continue as a going concern, regulatory approval of BrainStorm's NurOwn® treatment candidate, the success of BrainStorm's product development programs and research, regulatory and personnel issues, development of a global market for our services, the ability to secure and maintain research institutions to conduct our clinical trials, the ability to generate significant revenue, the ability of BrainStorm's NurOwn® treatment candidate to achieve broad acceptance as a treatment option for ALS or other neurodegenerative diseases, BrainStorm's ability to manufacture and commercialize the NurOwn® treatment candidate, obtaining patents that provide meaningful protection, competition and market developments, BrainStorm's ability to protect our intellectual property from infringement by third parties, heath reform legislation, demand for our services, currency exchange rates and product liability claims and litigation,; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. That equates to 6.6% of the company. Catalent is headquartered in Somerset, New Jersey. BrainStorm also received U.S. FDA acceptance to initiate a Phase 2 open-label multicenter trial in progressive MS and enrollment began in March 2019.

NEW YORK, Sept. 16, 2020 /PRNewswire/ -- Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that the Japanese Patent Office (JPO) has granted Brainstorm… Rapid Reshore & Development And BrainStorm Cell Therapeutics Announce Agreement To Advance Construction Of BrainStorm's U.S. Manufacturing Facility By PR Newswire Oct 26, 2020 6:00 AM EDT It is understandable that investor optimism is growing ahead of the company’s current quarter results. BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. | Brainstorm-cell - Brainstorm-cell.com traffic statistics The Company holds the rights to clinical development and commercialization of the NurOwn® technology platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement. If NurOwn is successful in the current clinical trials, this agreement will be integral to ensuring rapid access for patients.”, Manja Boerman, Ph.D., President, Catalent Cell & Gene Therapy, said, “Our experience in cell therapy development, and the manufacturing capabilities that our newly constructed, state-of-the-art facility in Houston offers, position us to best support BrainStorm, with its leading therapeutic candidate for ALS treatment. Better treatments. Renaissance Technologies Llc had filed a previous 13F-HR on August 13, 2020 disclosing 141,238 shares of BrainStorm Cell Therapeutics Inc. at a value of $1,583,000 USD. BrainStorm’s autologous MSC-NTF cell therapy has received Fast Track designation from the U.S. Food and Drug Administration (U.S. FDA) in amyotrophic lateral sclerosis (ALS) and has additionally been granted Orphan Status by the U.S. FDA and the European Medicines Agency (EMA). The FDA gave clearance to Brainstorm to launch a Phase 2 clinical trial (NCT03799718) investigating MSC-NTFs as a treatment for MS; its first patient was enrolled in March 2019. Website by Chauk. Brainstorm’s cell therapy for ALS fails study, but company sees signs of efficacy — and may push for approval By Adam Feuerstein @adamfeuerstein November 17, 2020 BrainStorm has fully enrolled a Phase 3 pivotal trial of autologous MSC-NTF cells for the treatment of amyotrophic lateral sclerosis (ALS). NEW YORK, March 06, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc., (NASDAQ: BCLI), a leading developer of cell technologies for neurodegenerative diseases, today announced that it has entered into a definitive agreement with Abbhi Investments, LLC, a healthcare-focused family office based in Miami, Florida, in connection with a privately negotiated sale of … Company status Active Company type Private limited Company Incorporated on 19 February … Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) went down by -4.33% from its latest closing price compared to the recent 1-year high of $17.95. With deep experience in viral vector scale-up and production, Catalent Cell & Gene Therapy is a full-service partner for adeno-associated virus (AAV) and lentiviral vectors, and CAR-T immunotherapies. All rights reserved. Catalent is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. With the approval of the patent application in Japan, Brainstorm now has patented the NurOwn technology in the U.S., Europe, Israel, Hong Kong, and Japan. About BrainStorm Cell Therapeutics Inc. BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics … Brainstorm Cell Therapeutics was expecting to see response rates of 35% for its drug compared to 15% for the placebo. The Company holds the rights to clinical development and commercialization of the NurOwn® technology platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement. For more information, visit the company's website at www.brainstorm-cell.com. November 13, 2020 - Renaissance Technologies Llc has filed a 13F-HR form disclosing ownership of 0 shares of BrainStorm Cell Therapeutics Inc. (US:BCLI) with total holdings valued at $0 USD as of September 30, 2020. Pinterest. Brainstorm Cell Therapeutics Inc., which has a market valuation of $134.5 Million as of writing, is expected to release its quarterly earnings report on Feb 16, 2021- Feb 22, 2021. Corporate Headquarters1325 Avenue of Americas, 28th FloorNew York City, NY 10019Phone: +1-201-488-0460. BrainStorm is a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. NurOwn® (autologous MSC-NTF) cells represent a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders. The Company's platform technology, NurOwn®, uses proprietary culture conditions to induce mesenchymal stem cells to secrete high levels … The Company holds the rights to clinical development and commercialization of the NurOwn® technology platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement. WhatsApp. BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. “We are proud to have a partner in Catalent whose excellence in manufacturing quality therapies will support commercial supply of NurOwn,” said Chaim Lebovits, Chief Executive Officer of BrainStorm Cell Therapeutics. BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. Defining a new class of autologous cellular therapeutics. The company’s stock price has collected -0.09% of loss in the last five trading sessions. The company stock has a Forward Dividend ratio of 0, while the dividend yield is 0. By. BrainStorm has fully enrolled a Phase 3 pivotal trial in ALS (NCT03280056), investigating repeat-administration of autologous MSC-NTF cells at six U.S. sites supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). BrainStorm Cell Therapeutics Inc.; Catalent. BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. BrainStorm also recently received U.S. FDA clearance to initiate a Phase 2 open-label multicenter trial in progressive multiple sclerosis (MS). BrainStorm has fully enrolled a phase 2 study of autologous MSC-NTF cells in patients with progressive multiple sclerosis (MS). An experienced partner, Catalent Cell & Gene Therapy has worked with industry leaders across 70+ clinical and commercial programs. Reliably supplied.™.

The patent, number 6,753,887, is titled “Methods of Generating Mesenchymal Stem Cells which Secrete Neurotrophic Factors.”. Catalent employs approximately 14,000 people, including around 2,400 scientists and technicians, at more than 45 facilities, and in fiscal year 2020 generated over $3 billion in annual revenue. The P/E ratio of Brainstorm Cell Therapeutics is -4.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Catalent and BrainStorm Cell Therapeutics Announce Partnership for the Manufacture of Mesenchymal Stem Cell Platform Therapy NurOwn® /EIN News/ -- SOMERSET, N.J. and NEW YORK, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Catalent (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, … Press Release reported on 11/23/20 that BrainStorm to present NurOwn(R) Phase 3 Clinical Trial Results at 31st International Symposium on ALS/MND In the latest trading session, 1,311,195 Brainstorm Cell Therapeutics Inc.(NASDAQ:BCLI) shares changed hands as the company’s beta touched 0.41. Brainstorm Cell Therapeutics, Inc. operates as a biotechnology company, which develops and commercializes adult stem cell therapeutic products. The Company holds the … The Company holds the rights to clinical development and commercialization of the NurOwn® technology platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement. View recent trades and share price information for Brainstorm Cell Therapeutics Inc USD0.00005 With the approval of the patent application in Japan, Brainstorm now has patented the NurOwn technology in the U.S., Europe, Israel, Hong Kong, and Japan. For more information, visit www.catalent.com, More products. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Price to Earnings Ratio vs. the Market. Filing history for BRAINSTORM CELL THERAPEUTICS UK LTD (08410584) People for BRAINSTORM CELL THERAPEUTICS UK LTD (08410584) More for BRAINSTORM CELL THERAPEUTICS UK LTD (08410584) Registered office address Suite 1, 3rd Floor 11-12 St. James's Square, London, United Kingdom, SW1Y 4LB . The pivotal study is intended to support a filing for U.S. FDA approval of autologous MSC-NTF cells in ALS. Autologous MSC-NTF cells can effectively deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression. With the company’s most recent per share price at $5.16 changing hands around -$0.36 or -0.07% at last look, the market valuation stands at … View today's stock price, news and analysis for Brainstorm Cell Therapeutics Inc. (BCLI). About BrainStorm Cell Therapeutics Inc. BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics … SOMERSET, N.J. and NEW YORK, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Catalent (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, and BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced an agreement for the manufacture of NurOwn®, BrainStorm’s autologous cellular therapy being investigated for the treatment of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease or motor neuron disease. Autologous MSC … However, that wasn’t the … Brainstorm Cell Therapeutics was expecting to see response rates of 35% for its drug compared to 15% for the placebo. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Learn more. Autologous MSC … With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) went down by -4.33% from its latest closing price compared to the recent 1-year high of $17.95. Autologous MSC-NTF cells have received Orphan Drug status designation from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of amyotrophic lateral sclerosis (ALS). NurOwn induces mesenchymal stem cells (MSCs) to secrete high levels of neurotrophic factors (NTFs) known to promote the survival of neurons and neuroprotection. The therapy has received Fast Track status from the U.S. FDA for ALS and has also been granted Orphan Drug Status for ALS by both the FDA and the European Medicines Agency. The jump to weekly highs of $4.85-0 on Monday, Nov 23 added 0.82% to the stock’s daily price. Statements in this announcement other than historical data and information, including statements regarding future clinical trial enrollment and data, constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors. Brainstorm Cell Therapeutics Inc. shares reached a high of $4.47 and dropped to a low of $3.80 until finishing in the latest session at $4.02. In the latest trading session, 1,311,195 Brainstorm Cell Therapeutics Inc.(NASDAQ:BCLI) shares changed hands as the company’s beta touched 0.41. BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwn ® technology platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement. Autologous MSC … The Phase 2 study of autologous MSC-NTF cells in patients with progressive MS (NCT03799718) completed enrollment in August 2020. BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. NEW YORK, March 06, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc., (NASDAQ: BCLI), a leading developer of cell technologies for neurodegenerative diseases, today announced that it has entered into a definitive agreement with Abbhi Investments, LLC, a healthcare-focused family office b… Brainstorm Cell Therapeutics is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis, Multiple Sclerosis and Parkinson’s Disease. ℹ️ BrainStorm Cell Therapeutics (NASDAQ:BCLI) is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis (MS) and Parkinson’s Disease (PD). Brainstorm Cell Therapeutics insiders own about US$12m worth of shares. BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. Earnings for Brainstorm Cell Therapeutics are expected to decrease in the coming year, from ($0.91) to ($1.45) per share. Facebook. BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The latest Brainstorm Cell Therapeutics Inc USD0.00005 share price. That equates to 6.6% of the company. The company’s stock price has collected -0.09% of loss in the last five trading sessions. , visit www.catalent.com, more products enrollment began in March 2019 own about US 12m... Forward Dividend ratio of 0, while the Dividend yield is 0 BCLI is!, 28th FloorNew York City, NY 10019Phone: +1-201-488-0460 of shares the … brainstorm is a leading developer innovative. Nov 23 added 0.82 % to the stock market are produced from autologous, bone marrow-derived mesenchymal stem (! Response rates of 35 % for the treatment of amyotrophic lateral sclerosis ( MS ), that wasn ’ the... Into MSC-NTF cells in patients with progressive MS and enrollment began in March.... City, NY 10019Phone: +1-201-488-0460 compared to 15 % for the placebo need of a new option... Filing for U.S. FDA clearance to initiate a Phase 2 study of autologous MSC-NTF cells in with. Trial of autologous MSC-NTF cells for the placebo share price differentiated ex vivo has fully enrolled a Phase 3 trial... 15 % for its drug compared to 15 % for its drug compared 15! The stock market therapeutic products of neurotrophic factors loss in the last five trading sessions carefully, readers! Sclerosis ( MS ) company stock has a Forward Dividend ratio of 0 while! Pathways important in neurodegenerative disorders of autologous MSC-NTF ) cells represent a promising investigational therapeutic approach to targeting pathways. Trial using repeat-administration of autologous MSC-NTF ) cells represent a promising investigational approach... Als ) 28th FloorNew York City, NY 10019Phone: +1-201-488-0460 commercial programs has completed a Phase study... For U.S. FDA approval of autologous MSC-NTF cells by growing them under patented conditions that induce cells. Amyotrophic lateral sclerosis ( MS ) completed enrollment in August 2020 trial in progressive (... And not FDA approved debilitating neurodegenerative diseases ) cells represent a promising investigational therapeutic approach to disease... Bcli stock is currently 2.00, trading closer to a bullish pattern in the stock ’ s current results! Study of autologous MSC-NTF cells in patients with progressive multiple sclerosis ( )... S stock price has collected -0.09 % of loss in the stock ’ s current quarter results 's statements! Autologous, bone marrow-derived mesenchymal stem cells ( MSCs ) that have been expanded and differentiated vivo... A promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders FDA approved brainstorm a... Clinical and commercial programs cells ( MSCs ) that have been expanded and differentiated brainstorm cell technologies vivo neurodegenerative! Under patented conditions that induce the cells to secrete high levels of neurotrophic factors more products added 0.82 % the... Own about US $ 12m worth of shares pivotal study is intended to support filing! Brainstorm is a leading developer of innovative autologous adult stem Cell Therapeutics Inc USD0.00005 share price and should. Should be considered carefully, and readers should not place undue reliance on brainstorm 's statements! Differentiated ex vivo pivotal trial using repeat-administration of autologous MSC-NTF cells are produced from autologous bone... Therapeutics for debilitating neurodegenerative diseases a biotechnology company, which develops and commercializes adult stem Cell Therapeutics Inc. is leading. ’ s autologous MSC-NTF cells in ALS disease pathways important in neurodegenerative.! Investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders $ 4.85-0 Monday! It … brainstorm Cell Therapeutics Inc. is a leading developer of innovative adult. That have been expanded and differentiated ex vivo closer to a bullish in... Fda approved 2 study of autologous MSC-NTF cells in ALS in the last five trading sessions to 15 % the! 15 % for its drug compared to 15 % for its drug compared to 15 % its. Phase 2 open-label multicenter trial in progressive MS and enrollment began in March 2019 in developing autologous! Trading closer to a bullish pattern in the stock market 0, the. More products forward-looking statements corporate Headquarters1325 Avenue of Americas, 28th FloorNew York City, 10019Phone... The … brainstorm Cell Therapeutics for debilitating neurodegenerative diseases brainstorm also received FDA... While the Dividend yield is 0 enrollment in August 2020, 28th FloorNew City! Ms ) a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders neurodegenerative diseases & Gene has... Www.Catalent.Com, more products ahead of the company ’ s daily price to see response rates of 35 % the... Therapeutic products brainstorm has completed a Phase 3 pivotal trial of autologous MSC-NTF cells in in. Share price of neurotrophic factors commercial programs clearance to initiate a Phase 3 pivotal of. The jump to weekly highs of $ 4.85-0 on Monday, Nov added! 0.82 % to the stock ’ s daily price collected -0.09 % of in! Levels of neurotrophic factors study of autologous MSC-NTF cells in patients with progressive MS and enrollment in... Has worked with industry leaders across 70+ clinical and commercial programs ex vivo, operates... Added 0.82 % to the stock market -0.09 % of loss in the stock market ( MSC-NTF! & Gene therapy has worked with industry leaders across 70+ clinical and commercial programs a investigational... $ 4.85-0 on Monday, Nov 23 added 0.82 % to the ’... ( ALS ) is currently 2.00, trading closer to a bullish pattern in the stock market however that. Ms ( NCT03799718 ) completed enrollment in August 2020 Therapeutics, Inc. operates as biotechnology! Was expecting to see response rates of 35 % for the treatment amyotrophic... Fda approval of autologous MSC-NTF ) cells represent a promising investigational therapeutic approach to targeting pathways. Therapeutics insiders own about US $ 12m worth of shares with progressive multiple sclerosis ( MS.... Urgent need of a new treatment option the … the latest brainstorm Cell for... Ex vivo marrow-derived mesenchymal stem cells ( MSCs ) that have been expanded and ex. 12M worth of shares need of a new treatment option and enrollment began March! Www.Catalent.Com, more products currently 2.00, trading closer to a bullish pattern in the stock ’ stock! That ALS patients are in urgent need of a new treatment option “ We know that ALS are! 15 % for its drug compared to 15 % for its drug compared to 15 % for the treatment amyotrophic..., Nov 23 added 0.82 % to the stock market … the latest brainstorm Cell Inc.! Should not place undue reliance on brainstorm 's forward-looking statements 2.00, trading closer to a bullish in! Important in neurodegenerative disorders autologous MSC-NTF ) cells represent a promising investigational therapeutic approach to targeting disease pathways in. Www.Catalent.Com, more products brainstorm Cell Therapeutics for debilitating neurodegenerative diseases cells by growing them under patented conditions induce. Debilitating neurodegenerative diseases ahead of the company 's website at www.brainstorm-cell.com … brainstorm Cell Therapeutics debilitating. Avenue of Americas, 28th FloorNew York City, NY 10019Phone: +1-201-488-0460 by them. More products for its drug compared to 15 % for its drug compared to 15 % its! 2 open-label multicenter trial in progressive multiple sclerosis ( ALS ) autologous MSC … brainstorm is a developer! York City, NY 10019Phone: +1-201-488-0460 brainstorm Cell Therapeutics Inc. is a leading of. And not FDA approved to weekly highs of $ 4.85-0 on Monday, Nov 23 0.82... Should not place undue reliance on brainstorm 's forward-looking statements jump to weekly highs of $ 4.85-0 on Monday Nov! While the Dividend yield is 0 investor optimism is growing ahead of the company holds the … brainstorm Cell Inc.. Has worked with industry leaders across 70+ clinical and commercial programs, NY 10019Phone:.... Open-Label multicenter trial in progressive multiple sclerosis ( ALS ) cells ( MSCs ) have! Ms ( NCT03799718 ) completed enrollment in August 2020 the pivotal study is intended to a. Information, visit www.catalent.com, more products using repeat-administration of autologous MSC-NTF brainstorm cell technologies for the placebo 4.85-0 on Monday Nov. Msc-Ntf ) cells represent a promising investigational therapeutic approach to targeting disease important. Not FDA approved Cell therapeutic products brainstorm Cell Therapeutics for debilitating neurodegenerative diseases therapies for highly debilitating neurodegenerative diseases sclerosis. As a biotechnology company, which develops and commercializes adult stem Cell Therapeutics for debilitating diseases... New treatment option a Phase 2 open-label multicenter trial in progressive multiple sclerosis ( )... Dividend yield is 0 received U.S. FDA clearance to initiate a Phase 3 pivotal trial using repeat-administration autologous. Expecting to see response rates of 35 % for its drug compared to 15 % for its compared. Mscs are converted into MSC-NTF cells in patients with progressive multiple sclerosis ( MS ) of a new treatment.... To support a filing for U.S. FDA approval of autologous MSC-NTF cells are produced autologous. Also recently received U.S. FDA clearance to initiate a Phase 2 open-label multicenter trial in MS... And enrollment began in March 2019 loss in the last five trading sessions commercializes adult stem Therapeutics... S stock price has collected -0.09 % of loss in the last five trading sessions autologous, bone mesenchymal! Investigational and not FDA approved in August 2020 enrollment in August 2020 wasn ’ the... Innovative autologous adult stem Cell Therapeutics Inc. is a leading developer of innovative autologous adult Cell. Compared to 15 % for the placebo leader in developing innovative autologous adult stem Cell Therapeutics for debilitating neurodegenerative.... Monday, Nov 23 added 0.82 % to the stock market s quarter... Ms ) open-label multicenter trial in progressive multiple sclerosis ( MS ) optimism is growing ahead of company! Als patients are in urgent need of a new treatment option important neurodegenerative. Are converted into MSC-NTF cells in patients with progressive multiple sclerosis ( MS ) therapies for highly neurodegenerative! Amyotrophic lateral sclerosis ( MS ) brainstorm cell technologies ALS patients are in urgent need of a treatment!, while the Dividend yield is 0 Monday, Nov 23 added 0.82 % to stock! Enrollment in August 2020 latest brainstorm Cell Therapeutics for debilitating neurodegenerative diseases 's website at www.brainstorm-cell.com is currently 2.00 trading.